**Core tip:** To determine whether status of chronic hepatitis B (CHB) affects clinical outcomes of hepatitis E virus (HEV) super-infections, we investigated immunological phases, hepatitis B virus (HBV) serum markers, HBV viral load and anti-viral treatments among 228 patients with HBV-HEV co-infection. Well-compensated patients were majorly affected by HEV super-infections, and hepatitis B e antigen-negative CHB patients had the worst clinical outcomes among non-cirrhotics. Lack of proper anti-HBV treatment may contribute to the worse outcomes. These data may help to facilitate development of vaccination programs that precisely target populations at risk of poor outcome from HBV-HEV co-infections.

INTRODUCTION
============

Viral hepatitis, including hepatitis A, B, C, D and E, causing acute or chronic liver diseases, represents severe threats to public health worldwide. In China, where the hepatitis B virus (HBV) is endemic, the rate of hepatitis B surface antigen (HBsAg) positivity among the general population remains around 7.2%, with 93 million people diagnosed as chronic HBV carriers despite the national HBV vaccination program. Chronic hepatitis B (CHB) and its related diseases lead to approximately 0.3 million deaths annually\[[@B1]\]. Infection with the hepatitis E virus (HEV) was previously thought limited to developing countries with poor sanitation, but it is gradually emerging as a prevalent disease in developed countries as well. HEV mainly causes sporadic symptomatic infections that are transmitted zoonotically and associated with several risk factors, including old age, male sex, socio-economic status (such as rural area dwelling) and occupational exposure\[[@B2]-[@B7]\]. On the other hand, the meat industry in China is in the stage of rapid development, rapidly replacing the traditional family farms, which can lead to increased viral spreading between domestic animals and contaminated meats will results in more human infections. Therefore, in areas where CHB is endemic, such as China, super-infections of HEV on the CHB background are not uncommon. In fact, it was reported that HBV-HEV co-infections represented 20%-40% of all symptomatic acute hepatitis E (AHE) infections\[[@B8]-[@B11]\].

It is well known that AHE superimposed on chronic liver diseases (CLDs), especially cirrhosis, frequently leads to severe disease, as exemplified by acute-on-chronic liver failure (ACLF)\[[@B8],[@B12],[@B13]\]. However, CLDs vary largely in their etiology, disease stages and treatments, and it is still unclear whether these factors affect the adverse clinical outcomes that have been observed with HEV super-infections. Research into such issues will provide valuable data for increasing the overall understanding of the devastating diseases caused by HEV super-infections and will facilitate the development of future vaccination programs to precisely targeting the risk populations at highest risk of having the worst outcome from HBV-HEV co-infections.

MATERIALS AND METHODS
=====================

Patients
--------

From September 2009 to September 2014, 635 acute HEV-infected patients (showing clinical acute hepatitis symptomology and anti-HEV immunoglobulin (Ig)M positivity) were admitted to the Shanghai Public Health Clinical Center, which represents the regional tertiary hospital for infectious diseases in Shanghai city, China. Four hundred and seven of those patients were excluded from this study due to pregnancy, other viral hepatitis etiology (*e.g*., hepatitis A, C or D virus) or infection with Epstein-Barr virus, herpes simplex virus, or human immunodeficiency virus; the remaining 228 HEV-HBV co-infection patients were included in this retrospective study (Figure [1](#F1){ref-type="fig"}).

![Flow chart of admitted hepatitis E virus-hepatitis B virus co-infected cases. Patients were confirmed as severe cases according to whether or not they had liver failure and/or liver decompensation. EBV: Epstein-Barr virus; HAV: Hepatitis A virus; HCV: Hepatitis C virus; HDV: Hepatitis D virus; HEV: Hepatitis E virus; HIV: Human immunodeficiency virus; HSV: Herpes simplex virus.](WJG-22-10388-g001){#F1}

Detection
---------

Anti-HEV IgM level was determined in serum from patients by use of enzyme-linked immunosorbent assay (ELISA) (MP Biomedicals Asia Pacific, Singapore). Liver function was assessed by measuring standard serum markers using a fully-automated biochemical analyzer (7600 Series; Hitachi, Tokyo, Japan). HBV DNA levels were quantified by real-time PCR (ABI 7500; Applied Biosystems Inc., Foster City, CA, United States), with lower detection limit of 500 copies/mL. HBV serological markers were detected by ELISA (ARCHITECT i2000 SR; Abbott, Wiesbaden, Germany). Routine blood panel was detected with an automated hematology analyzer (XT-2000i; Sysmex, Kobe, Japan). Prothrombin time (PT) was measured by an automatic coagulometer (STA-R; Diagnostica Stago, Asnieres-sur-Seine, France). The PT-international normalized ratio (INR) was calculated.

CHB and AHE diagnosis and definition of clinical outcomes
---------------------------------------------------------

CHB was confirmed by HBsAg and/or HBV DNA positivity over the previous 6 mo\[[@B14]\]. Cases of AHE were identified by two consecutive positive tests for anti-HEV IgM along with record of clinical acute hepatitis symptomology in the hospital's clinical database. Liver failure and liver decompensation, or both, were considered as the severe liver diseases in these cases. Diagnosis of liver failure was based upon INR ≥ 1.5 or prothrombin activity ≤ 40% and rapidly progressing jaundice, with total bilirubin at 10 times the upper limit of normal, or a daily increase of ≥ 17.1 μmol/L\[[@B15]\]. Liver decompensation was defined by acute development of one or more major complications of the liver, including ascites, hepatic encephalopathy (HE), gastrointestinal hemorrhage or bacterial infections\[[@B16]\]. Patient mortality was defined as death related to liver disease within 3 mo from the disease onset. Laboratory data on the day of admission were collected for analysis.

Liver cirrhosis, natural course of CHB, and anti-HBV therapy
------------------------------------------------------------

Cirrhosis was diagnosed based upon liver biopsy results and/or radiological evidence (computed tomography, abdominal ultrasound or magnetic resonance imaging showing nodular liver surface or evidence of increased portal venous pressure, such as splenomegaly or the presence of intra-abdominal collateral vessels)\[[@B17]\]. The four stages of the natural course of CHB were used in this study: immune tolerant (IT), immune clearance (IC), low or non-replication (LR), and reactivation (RA)\[[@B18]-[@B20]\]. The IT stage was defined by the presence of HBeAg, high levels of HBV DNA, normal or minimally elevated serum alanine aminotransferase (ALT), normal or minimal liver histological activity, and scant fibrosis. The IC stage was characterized by fluctuating but progressively decreasing HBV DNA levels, elevated ALT and hepatic necro-inflammation. The LR stage was defined by negativity for HBeAg and positivity for anti-hepatitis B e antigen (anti-HBe), undetectable or low levels of HBV DNA, persistently normal ALT levels and inactive liver histology. The RA stage was characterized by HBeAg negativity with anti-HBe positivity, detectable serum HBV DNA levels, ALT elevation and moderate or severe necro-inflammation with variable fibrosis on liver biopsy\[[@B20]\].

Pre-anti-HBV therapy was defined as taking nucleos/tide analogues (NUCs) for more than 3 mo before the disease onset. Post-anti-HBV therapy was defined as taking NUCs immediately after the diagnosis of HBV-HEV co-infections. Pre-anti-HBV therapy effectiveness was defined as \> 2 log decline in HBV DNA within 3 mo of treatment.

Medical history data
--------------------

Demographic data, information regarding alcohol consumption, cigarette usage and drug history, and information of past medical history were retrieved from the hospital's clinical database. Drug history focused on the prior exposure to potential hepatotoxic medication before the onset of current symptoms. For past medical history, the definition of other liver diseases was the presence of one or more of the following diseases: chronic hepatitis C, alcoholic liver disease, fatty liver, autoimmune liver diseases, schistosomiasis, primary hepatic carcinoma, hepatic cyst and hepatic hemangioma. In addition, the definition of other extrahepatic underlying diseases was the presence of one or more previous associated comorbidities affecting various relevant major organ systems, including diabetes, hypertension, chronic respiratory diseases (*e.g*., chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, tuberculosis, phthisis), chronic kidney diseases (*e.g*. kidney stone, renal cyst, chronic renal insufficiency, chronic glomerulonephritis) and extrahepatic tumors.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 18.0 software. Descriptive statistics (median and range for continuous variables, frequency and percentage for categorical variables) were used to summarize the baseline demographics and disease characteristics for HBV-HEV co-infected patients. The χ^2^ test or Fisher's exact test and Mann-Whitney *U* test or ANOVA test were used to compare categorical and continuous variables, respectively. Categorical variables included baseline characteristics (*i.e*., smoker, sex), liver complications (*i.e*., ascites, HE), adverse clinical outcomes (*i.e*., severe diseases, mortality) and medical history information (*i.e*., diabetes, chronic respiratory diseases). Continuous variables included age, laboratory parameters, jaundice and HBV DNA. Multivariate logistic analysis was used for examining the risk factors for severe liver diseases and patient mortality in non-cirrhotic and cirrhotic HBV-HEV co-infected patients, respectively. *P* values \< 0.05 were considered statistically significant.

RESULTS
=======

HEV super-infections led to severe adverse outcomes in both cirrhotic and non-cirrhotic CHB patients
----------------------------------------------------------------------------------------------------

The data showed that HEV super-infections led to severe adverse outcomes, with 48.7% of the patients having liver failure and/or decompensation and the short-term mortality rate reaching 13.2% (Table [1](#T1){ref-type="table"}). Since 94 (41.2%) patients had pre-existing CHB-related cirrhosis, which generated worse clinical outcomes by HEV super-infections, we further compared the clinical features and laboratory parameters between the cirrhotic and non-cirrhotic patients (Table [1](#T1){ref-type="table"}). HEV super-infections were found to cause much more severe diseases with significantly more liver complication events in the cirrhotic patients (77.7%; Table [1](#T1){ref-type="table"}) and their short-term mortality rate was nearly 20%. These findings were significantly different than those in the non-cirrhotic patients (*vs* 28.4%, *P* \< 0.001 and *vs* 7.5%, *P* = 0.002, respectively). The cirrhotic and non-cirrhotic patients also differed significantly in findings from several biochemistry tests; specifically, levels of transaminase, serum albumin, platelets and leukocytes were all significantly lower, but INR was significantly higher in the cirrhotic patients (Table [1](#T1){ref-type="table"}).

###### 

Baseline demographic characteristics, clinical features and laboratory data for hepatitis B virus-hepatitis E virus co-infected patients

  **Characteristic**             **Total patients**   **Cirrhotic patients**   **Non-cirrhotic patients**   ***P* value**
  ------------------------------ -------------------- ------------------------ ---------------------------- ---------------
  Baseline characteristics                                                                                  
  Age (yr) (Q1-Q3)               49 (37-58)           55 (44.8-62.3)           44 (35.0-53.3)               \< 0.001
  Male sex, *n* (%)              167 (73.3)           74 (78.7)                93 (69.4)                    0.118
  Alcohol, *n* (%)               74 (34.5)            37 (39.4)                37 (27.6)                    0.062
  Smoker, *n* (%)                72 (31.6)            30 (31.9)                42 (31.3)                    0.927
  Clinical features, *n* (%)                                                                                
  Bilirubin \> 10-fold ULN       76 (33.3)            33 (35.1)                43 (32.1)                    0.634
  Ascites                        83 (36.4)            62 (66)                  21 (15.7)                    \< 0.001
  Infection                      73 (32)              47 (50)                  26 (19.4)                    \< 0.001
  HE                             39 (17.1)            24 (25.5)                15 (11.2)                    \< 0.010
  GH                             11 (4.8)             11 (11.7)                0                            \< 0.001
  Outcomes of disease, *n* (%)                                                                              
  Severe disease                 111 (48.7)           73 (77.7)                38 (28.4)                    \< 0.001
  Mortality                      30 (13.2)            20 (21.3)                10 (7.5)                     \< 0.010
  Laboratory parameters                                                                                     
  ALT (IU/L)                     239.5 (62.5-773.5)   115 (10.8-456.8)         429.5 (89.8-966.8)           \< 0.001
  AST (IU/L)                     144 (63-422.5)       112 (54.5-364.5)         185 (74.5-475.0)             0.077
  Tbil (μmol/L)                  61.5 (19.0-257.6)    68.1 (22.8-296.5)        59.6 (16.9-246.8)            0.245
  ALB (g/dL)                     37.8 (32.1-40)       33.1 (28.7-36.7)         38.1 (34.4-40.9)             \< 0.001
  INR                            1.2 (1.0-1.6)        1.4 (1.2-1.8)            1.1 (1.0-1.3)                \< 0.001
  LEU count (10^9^/L)            5.3 (4.1-7.1)        4.6 (3.3-6.6)            6.0 (4.6-7.2)                \< 0.001
  Platelet count (10^9^/L)       115 (78-163)         83 (53.8-114.3)          147.5 (97.8-182.3)           \< 0.001
  NEU count (10^9^/L)            1.4 (1.0-1.9)        1.1 (0.8-1.5)            1.7 (1.2-2.2)                0.080

Data are presented as median (Q1-Q3) and number of patients (%). Severe disease was defined as liver failure and/or liver decompensation. ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GH: Gastrointestinal hemorrhage; HE: Hepatic encephalopathy; INR: International normalized ratio; LEU: Leukocytes; NEU: Neutrophil; Tbil: Total bilirubin; ULN: Upper limit of normal.

Disease stage, HBV markers, anti-HBV therapy and pre-existing comorbidities as related to clinical outcomes in cirrhotic HBV-HEV co-infected patients
-----------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether clinical outcomes would be affected by the severity of underlying cirrhosis, patients with decompensated and well-compensated cirrhosis were compared. There were only 9 decompensated patients (9.6%), in contrast to the 85 well-compensated ones. Except for a higher proportion of HE in the decompensated group (66.7% *vs* well-compensated group: 21.2%, *P* = 0.008), there was no difference in short-term mortality rates (21.2% *vs* 22.2%, *P* = 0.973), and biochemistry tests between the two groups were also similar (Table [2](#T2){ref-type="table"}).

###### 

Clinical features and laboratory data for hepatitis B virus-hepatitis E virus co-infected patients with underlying decompensated or compensated liver cirrhosis *n* (%)

  **Characteristic**         **Decompensated**   **Compensated**     ***P* value**
  -------------------------- ------------------- ------------------- ---------------
  Baseline characteristics                                           
  Age, yr (Q1-Q3)            58 (54.0-62.5)      55 (41.5-62.5)      0.183
  Male sex                   8 (88.9)            66 (77.7)           0.679
  Alcohol                    2 (22.2)            35 (41.2)           0.475
  Smoker                     3 (33.3)            27 (31.8)           0.982
  Clinical features                                                  
  Bilirubin \> 10-fold ULN   2 (22.2)            32 (37.7)           0.480
  Ascites                    8 (88.9)            54 (63.5)           0.160
  Infection                  6 (66.7)            41 (48.2)           0.486
  HE                         6 (66.7)            18 (21.2)           \< 0.010
  GH                         1 (11.1)            10 (11.8)           0.982
  Outcomes of disease                                                
  Severe disease             9 (100)             64 (75.3)           0.200
  Mortality                  2 (22.2)            18 (21.2)           0.973
  Laboratory parameters                                              
  ALT ( IU/L)                51 (37.0-114.5)     122 (41.5-545.0)    0.094
  AST (IU/L)                 81 (49.0-188.5)     118 (53.0-399.5)    0.253
  Tbil (μmol/L)              39.5 (22.5-165.8)   85.7 (22.4-322.4)   0.433
  ALB (g/dL)                 28.7 (26.6-34.9)    33.2 (29.1-37.3)    0.114
  INR                        1.5 (1.2-1.6)       1.4 (1.2-1.8)       0.995
  LEU count (10^9^/L)        3.9 (2.0-7.5)       4.6 (3.5-6.3)       0.516
  Platelet count (10^9^/L)   54 (44.0-84.5)      85 (58.8-117.3)     0.080
  NEU count (10^9^/L)        2.8 (1.2-6.4)       3.0 (1.8-4.4)       0.933

Data are presented as median (Q1-Q3) and number of patients (%). Severe disease was defined as liver failure and/or liver decompensation. ALB: Albumin; ALT: Alanine aminotransferase; AST; Aspartate aminotransferase; GH: Gastrointestinal hemorrhage; HE: Hepatic encephalopathy; INR: International normalized ratio; LEU: Leukocytes; NEU: Neutrophil; Tbil: Total bilirubin; ULN: Upper limit of normal.

When examining the roles of HBV-related markers and anti-viral therapy, extremely low rates of anti-HBV treatment, both pre- (28.7%) and post- (42.6%), were unexpectedly identified. Consistent with this low level of anti-viral therapy, \> 70% of the cirrhotic patients had positive HBV DNA tests and \> 40% even had high levels of HBV DNA (\> 5 × 10^5^ IU/mL; Table [3](#T3){ref-type="table"}). Although anti-HBV therapy was not significantly associated with clinical outcomes, higher percentages of pre- and post-anti-viral therapy were found respectively in patients with mild diseases (38.1% *vs* 26.0%, *P* = 0.281 in patients with severe diseases; Table [3](#T3){ref-type="table"}) and surviving cases (52.8% *vs* 30.0%, *P* = 0.081 in fatal cases; Supplementary Table [1](#T1){ref-type="table"}).

###### 

Previous comorbidities, chronic hepatitis B-related status and disease severity for co-infected cirrhotic patients *n* (%)

                                        **Cirrhotic**    **Severe**       **Mild**     ***P* value**
  ------------------------------------- ---------------- ---------------- ------------ ---------------
  Baseline characteristics                                                             
  Age (yr) (Q1-Q3)                      55 (44.8-62.3)   56 (45.5-62.5)   52 (38-62)   0.254
  Male sex                              74 (78.7)        61 (83.6)        13 (61.9)    0.065
  Smoker                                30 (31.9)        27 (37)          3 (14.3)     \< 0.050
  Alcohol                               37 (39.4)        31 (42.5)        6 (28.6)     0.251
  Potential hepatoxic medications       8 (8.5)          8 (11)           0            0.192
  Pre-existing comorbidities, *n* (%)                                                  
  Hypertension                          12 (12.8)        8 (11)           4 (19.1)     0.456
  Diabetes                              10 (10.6)        9 (12.3)         1 (4.8)      0.448
  Respiratory diseases                  4 (4.3)          4 (5.5)          0            0.572
  Kidney diseases                       10 (10.6)        9 (12.3)         1 (4.8)      0.448
  Other liver diseases                  24 (25.5)        21 (28.8)        3 (14.3)     0.180
  HBeAg positivity                      32 (34)          22 (30.1)        10 (47.6)    0.136
  HBV DNA positivity                    69 (73.4)        52 (71.2)        17 (81)      0.374
  HBV DNA \< 500 IU/mL                  25 (26.6)        21 (28.8)        4 (19.1)     0.374
  500 ≤ HBV DNA \< 5 × 10^5^ IU/mL      31 (33)          22 (30.1)        9 (42.9)     0.275
  HBV DNA ≥ 5 × 10^5^ IU/mL             38 (40.4)        30 (41.1)        8 (38.1)     0.805
  Pre-anti-HBV therapy                  27 (28.7)        19 (26)          8 (38.1)     0.281
  Effective                             11 (11.7)        9 (12.3)         2 (9.5)      0.982
  Post-anti-HBV therapy                 40 (42.6)        34 (46.6)        6 (28.6)     0.141

Data are presented as median (Q1-Q3) or number of patients (%). The severe cases included patients with liver failure, liver decompensation or both; The remaining were regarded as mild cases. Respiratory diseases: chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, tuberculosis, phthisis; Kidney diseases: kidney stone, renal cyst, chronic renal insufficiency, chronic glomerulonephritis; Other liver diseases: chronic hepatitis C, alcoholic liver disease, fatty liver, autoimmune liver diseases, schistosomiasis, primary hepatic carcinoma, hepatic cyst, hepatic hemangioma. Pre-anti-hepatitis B virus (HBV) therapy consisted of nucleos/tide analogues for more than 3 mo before the disease onset; Post-anti-HBV therapy consisted of IFNα within 3 mo from the disease onset; Therapeutic efficacy was defined as HBV DNA reduction by 2 log after stable antiviral treatment for 3 mo.

Finally, male sex (OR: 3.1, *P* = 0.038) and alcohol usage (OR: 3.5, *P* = 0.060; Supplementary Table [2](#T2){ref-type="table"}) were identified to be likely associated with severe diseases in cirrhotic patients, while pre-existing kidney disease was linked to short-term mortality among cirrhotic patients with severe liver diseases (OR: 13.7, *P* = 0.008; Supplementary Table [3](#T3){ref-type="table"}).

Disease stage, HBV markers, anti-HBV therapy and pre-existing comorbidities as related to clinical outcomes in non-cirrhotic HBV-HEV co-infected patients
---------------------------------------------------------------------------------------------------------------------------------------------------------

The RA group, or the HBeAg-negative CHB patients, had the worst outcomes among different stages of CHB (Table [4](#T4){ref-type="table"}). The proportions of severe diseases (liver failure and/or decompensation) and short-term mortality were 41.5% and 17.0%, respectively, which were highest among non-cirrhotic groups and even close to the figures observed in cirrhotic patients (41.5% *vs* 77.7% and 17% *vs* 21.3% respectively; Table [1](#T1){ref-type="table"} and Table [4](#T4){ref-type="table"}). In contrast, the incidence of severe diseases (13.2%) and mortality (2.6%) was lowest in IT patients, while the proportions in the IC and LR group fell between those for the IT and RA groups (Table [4](#T4){ref-type="table"}). Regarding findings from the biochemistry tests, the different CHB groups also differed significantly in their level of serum bilirubin (*P* = 0.000), INR (*P* = 0.015) and level of leukocytes (*P* = 0.035).

###### 

Clinical features and laboratory data for patients with non-cirrhotic hepatitis B virus-hepatitis E virus co-infections *n* (%)

  **Characteristic**         **IT**               **IC**              **LC**                  **RA**               ***P* value**
  -------------------------- -------------------- ------------------- ----------------------- -------------------- ---------------
  Baseline characteristics                                                                                         
  Age (yr ) (Q1-Q3)          43 (30-52)           42 (34-51)          48 (39.3-58.8)          47 (36.0-56.5)       0.134
  Male sex                   17 (44.7)            22 (81.5)           13 (81.3)               41 (77.4)            \< 0.010
  Alcohol                    7 (18.4)             5 (18.5)            5 (31.3)                20 (37.7)            0.136
  Smoker                     8 (21.1)             8 (29.6)            4 (25)                  22 (41.5)            0.191
  Clinical features                                                                                                
  Jaundice \> 10 ULN         6 (15.8)             6 (22.2)            6 (37.5)                25 (47.2)            \< 0.010
  Ascites                    4 (10.5)             3 (11.1)            0                       14 (26.4)            \< 0.050
  Infection                  4 (10.5)             2 (7.4)             4 (25)                  16 (30.2)            \< 0.050
  HE                         1 (2.6)              1 (3.7)             0                       13 (24.5)            \< 0.010
  Outcomes of disease                                                                                              
  Severe disease             5 (13.2)             6 (22.2)            5 (31.3)                22 (41.5)            \< 0.050
  Mortality                  1 (2.6)              0                   0                       9 (17)               \< 0.010
  Laboratory parameters                                                                                            
  ALT (IU/L)                 276.5 (77.5-520.5)   454 (214-822)       597.5 (156.75-1188.5)   447 (70-1034.5)      0.231
  AST (IU/L)                 162 (66.3-471.0)     186 (108-527)       266 (55.5-841.0)        200 (70.5-421.0)     0.854
  Tbil (μmol/L)              22.1 (10.5-42.9)     38.8 (15.0-162.3)   160.3 (63.9-205.5)      148.4 (29.8-339.0)   \< 0.001
  ALB (g/dL)                 38.4 (35.0-40.8)     39.4 (35.1-42.0)    36.5 (32.9-39.4)        36.5 (33.5-41.2)     0.199
  INR                        1.1 (1.0-1.2)        1.1 (1.0-1.2)       1.1 (0.9-1.3)           1.1 (1-2)            \< 0.050
  LEU count (10^9^/L)        5 (4.3-6.5)          6.2 (5.0-6.9)       7.2 (5.4-9.0)           6.1 (4.4-7.1)        \< 0.050
  Platelet count (10^9^/L)   155 (102.3-205.3)    149 (103-190)       177.5 (124.3-200.0)     126 (93-159)         0.072
  NEU count (10^9^/L)        2.7 (2.3-3.7)        3.4 (2.8-4.2)       3.9 (2.8-5.5)           3.7 (2.1-4.8)        0.144

Data are presented as median (Q1-Q3) and number of patients (%). Severe disease was defined as liver failure and/or liver decompensation. ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HE: Hepatic encephalopathy; INR: International normalized ratio; LEU: Leukocytes; NEU: Neutrophil; Tbil: Total bilirubin; ULN: Upper limit of normal.

Next, we assessed the involvement of HBV markers, anti-HBV therapy and other host factors in the development of adverse clinical outcomes among the non-cirrhotic patients (Table [5](#T5){ref-type="table"}). Proportions of HBeAg positivity (29.0% *vs* 56.3%, *P* = 0.004) and high HBV DNA levels (\> 5 × 10^5^ IU/mL; 29.0% *vs* 53.1%, *P* = 0.011) were much lower, while the proportion with intermediate HBV DNA levels (500-5 × 10^5^ IU/mL; 47.4% *vs* 18.8%, *P* = 0.001) was much higher in the non-cirrhotic patients with severe liver diseases.

###### 

Previous comorbidities, chronic hepatitis B related status and disease severity for co-infected non-cirrhotic patients *n* (%)

  **Characteristic**                 **Non-cirrhotic (*n* = 134)**   **Severe (*n* = 38)**   **Mild (*n* = 96)**   ***P* value**
  ---------------------------------- ------------------------------- ----------------------- --------------------- ---------------
  Baseline characteristics                                                                                         
  Age (yr) (Q1-Q3)                   44 (35-53.3)                    47.5 (36-56.3)          44 (32.5-53)          0.167
  Male sex                           93 (69.4)                       30 (80.0)               63 (65.6)             0.131
  Alcohol                            37 (27.6)                       18 (47.4)               19 (19.8)             \< 0.010
  Smoker                             42 (31.3)                       16 (42.1)               26 (27.1)             0.091
  Potential hepatoxic medications    18 (13.4)                       9 (23.7)                9 (9.4)               \< 0.050
  Pre-existing comorbidities                                                                                       
  Hypertension                       13 (9.7)                        4 (10.5)                9 (9.4)               0.986
  Diabetes                           15 (11.2)                       9 (23.7)                6 (6.3)               \< 0.050
  Respiratory diseases               9 (6.7)                         3 (7.9)                 6 (6.3)               0.713
  Kidney diseases                    10 (7.5)                        8 (21.1)                2 (2.1)               \< 0.010
  Extrahepatic tumors                2 (1.5)                         1 (2.6)                 1 (1.0)               0.488
  Other liver diseases               24 (17.9)                       6 (15.8)                18 (18.8)             0.687
  HBeAg positive                     65 (48.5)                       11 (29.0)               54 (56.3)             \< 0.010
  HBV DNA positivity                 98 (73.1)                       29 (76.3)               69 (71.9)             0.601
  HBV DNA \< 500 IU/mL               36 (26.9)                       9 (23.7)                27 (28.1)             0.556
  500 ≤ HBV DNA \< 5 × 10^5^ IU/mL   36 (26.9)                       18 (47.4)               18 (18.8)             \< 0.010
  HBV DNA ≥ 5 × 10^5^ IU/mL          62 (46.3)                       11 (29.0)               51 (53.1)             \< 0.050
  Pre-anti-HBV therapy               12 (9)                          2 (5.3)                 10 (10.4)             0.508
  Effective                          3 (2.2)                         1 (2.6)                 2 (2.1)               0.991
  Post-anti-HBV therapy              30 (22.4)                       10 (26.3)               20 (20.8)             0.493

Data are presented as median (Q1-Q3) or number of patients (%). P value was derived from comparisons between mild and severe cases. The severe cases included patients with liver failure, liver decompensation or both; The remaining were regarded as mild cases. Respiratory diseases: chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, tuberculosis, phthisis; Kidney diseases: kidney stone, renal cyst, chronic renal insufficiency, chronic glomerulonephritis; Other liver diseases: chronic hepatitis C, alcoholic liver disease, fatty liver, autoimmune liver diseases, schistosomiasis, primary hepatic carcinoma, hepatic cyst, hepatic hemangioma. Pre-anti-hepatitis B virus (HBV) therapy consisted of nucleos/tide analogues for more than 3 mo before the disease onset; Post-anti-HBV therapy consisted of IFNα within 3 mo from the disease onset; Therapeutic efficacy was defined as HBV DNA reduction by 2 log after stable antiviral treatment for 3 mo.

We further found that both the pre- and post-anti-HBV treatment rates were extremely low in the non-cirrhotic CHB patients, only 9.0% and 22.4% respectively. The low number of treated patients precluded any significant result from the statistical analysis; however, a higher percentage of previous anti-HBV therapy was still noted for the patients with mild disease (10.4% *vs* 5.3%, *P* = 0.508) (Table [5](#T5){ref-type="table"}).

In addition, alcohol consumption (OR: 6.4, *P* = 0.020), pre-existing diabetes (OR: 7.5, *P* = 0.003) and kidney diseases (OR: 12.7, *P* = 0.005) were identified as independent predictors for severe diseases by the multivariate logistic regression analysis with adjustment for confounding factors (Table [6](#T6){ref-type="table"}).

###### 

Risk factors for disease severity in non-cirrhotic hepatitis B virus-hepatitis E virus co-infection

  **Risk factors**                     **Odds ratio for severe liver diseases**                              
  ------------------------------------ ------------------------------------------ --------- ---------------- ---------
  Non-cirrhotic patients (*n* = 134)                                                                         
  Male sex                             2 (0.8-4.8)                                0.135                      
  Age                                  1 (0.9-1.1)                                0.135                      
  Alcohol                              3.7 (1.6-8.2)                              \< 0.01   6.4 (1.3-31.4)   \< 0.05
  Smoker                               2.8 (1.2-6.7)                              \< 0.05   0.4 (0.1-2.4)    0.341
  Potential hepatoxic medications      3 (1.1-8.3)                                \< 0.05   2 (0.56-7.2)     0.296
  Diabetes                             4.7 (1.5-14.2)                             \< 0.01   7.5 (2-28.5)     \< 0.01
  Hypertension                         1.1 (0.3-3.9)                              0.839                      
  Respiratory diseases                 1.3 (0.3-5.4)                              0.732                      
  Kidney diseases                      12.5 (2.5-62.3)                            \< 0.01   12.7 (2.1-76)    \< 0.01
  Extrahepatic tumors                  2.6 (0.2-42.1)                             0.509                      
  Other liver disease                  0.8 (0.3-2.2)                              0.687                      
  HBeAg positive                       0.3 (0.1-0.7)                              \< 0.01   0.4 (0.1-1.3)    0.118
  HBV DNA status                                                                                             
  HBV DNA \< 500 IU/mL                 Reference                                  \< 0.01   Reference        \< 0.05
  500 ≤ HBV DNA \< 5 × 10^5^ IU/mL     3 (1.1-8.1)                                \< 0.05   5.1 (1.4-18.2)   \< 0.05
  HBV DNA ≥ 5 × 10^5^ IU/mL            0.7 (0.2-1.8)                              0.392     2 (0.5-8.6)      0.347
  Pre-anti-HBV therapy                 0.5 (0.1-2.3)                              0.356                      
  Effective                            1.3 (0.1-14.4)                             0.847                      
  Post-anti-HBV therapy                1.4 (0.6-3.3)                              0.493                      

Odds ratio (95%CI) and *P* value refer to single factor analysis;

Odds ratio (95%CI) and *P* value correspond to multivariate logistic regression results. With hepatitis B virus (HBV) DNA \< 500 IU/mL as reference category respectively. Multivariate logistic regression models were used to assess the association between various risk factors and severe disease. The severe cases included patients with liver failure, liver decompensation or both; The remaining were regarded as mild cases. Respiratory diseases: chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis, tuberculosis, phthisis; Kidney diseases: kidney stone, renal cyst, chronic renal insufficiency, chronic glomerulonephritis; Other liver diseases: chronic hepatitis C, alcoholic liver disease, fatty liver, autoimmune liver diseases, schistosomiasis, primary hepatic carcinoma, hepatic cyst, hepatic hemangioma. Pre-anti-HBV therapy consisted of nucleos/tide analogues for more than 3 mo before the disease onset; Post-anti-HBV therapy consisted of IFNα within 3 mo from the disease onset; Therapeutic efficacy was defined as HBV DNA reduction by 2 log after stable antiviral treatment for 3 mo.

DISCUSSION
==========

Despite the national HBV vaccination campaign in China, HBV remains endemic, with 7% of the total Chinese population identified as afflicted with CHB\[[@B21],[@B22]\]. Meanwhile, recent epidemiological study in China has indicated a past HEV infection rate of 20%-40% (anti-HEV IgG positivity) and an additional 1% of new infections annually\[[@B23]-[@B25]\]. Due to such high prevalence of HBV and HEV, co-infections by both viruses are not rare in China and nearly 20%-40% of all symptomatic HEV infections were determined to occur on CHB backgrounds, as reported previously and observed in the present study\[[@B7]-[@B10]\]. On one hand, the underlying CHB could predispose the co-infected patients to more severe symptoms than HEV mono-infections\[[@B10],[@B11]\]. On the other hand, HEV infection may also aggravate the clinical outcome of HBV infection, especially under conditions of liver cirrhosis\[[@B26]\]. Notably, HEV super-infections were reported as the second most prevalent precipitating factor in triggering ACLF in CHB patients\[[@B27],[@B28]\], revealing a mutual influence among the viral co-infections. However, CHB patients vary significantly in their stages of infection, viral activity, treatment strategies and liver functional reserves\[[@B14]\], all of which can greatly affect clinical outcomes during HEV super-infections. To characterize the roles of these HBV-related factors, we analyzed a large dataset of 228 HBV-HEV co-infected patients retrospectively.

Underlying HBV-related cirrhosis is a crucial determining factor for disease severity\[[@B11]\]. Most cirrhotic patients with superimposed HEV-infections in our study presented with liver failure, decompensation or both, as compared to the non-cirrhotics. Interestingly, comparison of patients with prior compensated cirrhosis to those with decompensated cirrhosis showed no difference in short-term mortality rates for the two groups. This finding was surprising but in agreement with the recent studies on ACLF; whereas, the short-term mortality in patients with prior decompensation were not worse than that in compensated patients\[[@B16],[@B28]\]. Additionally, a small proportion of previously-decompensated patients was identified in the current study, indicating that HEV superinfection was a major threat to well-compensated cirrhotic patients.

Cirrhosis is considered prerequisite for ALCF in Western countries; however, in Asia, it is well recognized that ACLF can develop in non-cirrhotic patients, such as the CHB patients\[[@B13],[@B29]\]. To date, little is known regarding the incidence of and risk factors for ACLF in non-cirrhotics. In the present study, we found a continuous increase in incidence of liver failure and decompensation that followed the progression of CHB in co-infected patients. Although the observed outcomes in our study were liver failure and decompensation, distinctive from the definition of ACLF, these data still strongly suggested that no such distinct predisposing boundary existed for ACLF between the cirrhotic patients and non-cirrhotic patients. For example, the proportions of severe diseases and mortality in non-cirrhotic RA patients were not far from those in the cirrhotics. Therefore, these data indicate the involvement of underlying liver functional reserves in the subsequent development of more severe diseases in non-cirrhotics, suggesting that patients with HBeAg-negative CHB are the most vulnerable CHB population for symptomatic HEV infections and should be targeted for possible prophylactic vaccination\[[@B30]\]. Consistent with this theory, HBeAg negativity and intermediate HBV DNA levels were identified as independent predictors for adverse outcomes in co-infected non-cirrhotics.

Successful anti-HBV treatment can significantly reduce the adverse clinical outcomes in CHB patients, even in patients with decompensated cirrhosis\[[@B31]-[@B33]\]. Therefore, it is tempting to ask whether clearance of HBV would also affect the disease severity and mortality in HBV-HEV co-infections. No conclusions regarding this issue could be made from the data of previous studies, probably due to the mixed analysis of cirrhotic and non-cirrhotic patients and the relatively small sample sizes\[[@B10],[@B11]\]. In the present study, we were able to see a trend towards higher pre-treatment rates in both cirrhotic and non-cirrhotic subgroups when comparing patients with mild versus severe liver diseases. We also found a remarkably low proportion of previous anti-viral treatment in our HBV-HEV co-infected cohort. Moreover, regarding anti-HBV treatment after the onset of HEV super-infections, which may help to control potential HBV-reactivation, we found that the overall proportions of patients receiving anti-viral treatment were also low. Yet, we found a trend towards a higher percentage of post-anti-HBV treatment in the cirrhotic patients who survived. It is tempting to speculate that such low rates of both pre- and post-antiviral therapy were likely to contribute to the adverse outcomes in co-infected patients. Although the small number of samples precluded our ability to detect any statistically significant differences, we still strongly believe that appropriate and effective treatment will help to substantially reduce the incidence of symptomatic HEV super-infections and to prevent its related adverse outcomes.

Furthermore, we assessed the link between some pre-existing comorbidities and the adverse clinical outcomes in co-infected patients. We identified alcohol intake, previous diabetes and chronic kidney diseases as independent predictors, in addition to HBV markers. Previous studies have also identified alcohol use as a risk factor for HEV-infection and disease severity\[[@B7],[@B34]\]. It is well known that kidney function may become detrimentally impacted by liver failure\[[@B35],[@B36]\]. Accordingly, underlying kidney diseases might predispose HBV-HEV-infected patients to subsequent kidney failure in the setting of severe liver injury, which in turn may lead to multi-organ failure and will almost certainly increase the mortality rate. In addition, our data was in agreement with that in a previous report which demonstrated diabetes as an independent risk factor for severe viral hepatitis\[[@B37]\]. Therefore, treating clinicians should pay close attention to the possibility of superimposed HEV infection in CHB patients with underlying diabetes and kidney diseases, as it might lead to worse outcomes, especially if left undiagnosed.

Several limitations inherent to our retrospective study design must be considered when interpreting our findings. Since the analyzed data were retrieved from the clinical database of our hospital, we may have missed some crucial data that would have been otherwise recognized in a prospective analysis of the patients. Some diagnoses may have been inaccurate, and we had no control over the follow-up duration (by which we may have gained insight into longer-term outcomes). However, as highlighted in this article, our cohort of HBV-HEV co-infected patients was much larger than in previous studies and might compensate for the above-mentioned limitations. The major findings reported here were strongly supported by the data, which ultimately contribute to a better understanding of HEV-HBV co-infections.

ACKNOWLEDGMENTS
===============

We thank Dr. Jianjun Sun (Shanghai Public Health Clinical Center), Prof. Hongying Shi and Dr. Wenyue Liu (Wenzhou Medical University) for their assistance in statistical analysis, and all the staff in charge of the clinical database for their assistance in data acquisition.

COMMENTS
========

Background
----------

Superimposed acute hepatitis E (AHE) on chronic liver diseases (CLDs) often led to severe diseases, such as acute-on-chronic liver failure. However, CLDs vary largely in their etiology, disease stages and treatments, and it remains unclear whether these factors affect the adverse clinical outcomes of HEV super-infections. In areas such as China where chronic hepatitis B (CHB) is endemic, super-infections by hepatitis E virus (HEV) on the CHB background are not uncommon, but the clinical features and the risk factors for adverse outcomes in CHB superimposed with HEV are not clear.

Research frontiers
------------------

This research investigated CHB-related cirrhosis, immunological phases, hepatitis B virus (HBV) serum markers, HBV viral load and anti-viral treatments among a large cohort of HBV-HEV co-infected patients to explore the clinical features and risk factors for adverse outcomes in patients with CHB superimposed with HEV. This study provides valuable data for understanding the devastating diseases caused by HEV-HBV super-infections.

Innovations and breakthroughs
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Underlying CHB-related cirrhosis was found to pose a great risk for adverse outcomes in patients with superimposed AHE. Hepatitis B e antigen-negative CHB and intermediate HBV DNA levels were shown to be associated with severe diseases in non-cirrhotic super-infected patients. The rather low rate of anti-HBV therapy suggested that successful antiviral treatment might reduce the risks of superimposed AHE.

Applications
------------

This study provides valuable data for understanding the devastating diseases caused by HEV-HBV super-infections and may facilitate the HEV vaccination program to precisely target populations most at risk of poor outcomes.
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Acute hepatitis E was defined as clinical acute hepatitis symptomology and anti-HEV immunoglobulin M positivity. Chronic hepatitis B was confirmed by positivity for hepatitis B surface antigen and/or HBV DNA within the previous 6 mo. Super-infection was defined as a second infection superimposed on an earlier one, especially by a different microbial agent of exogenous or endogenous origin.
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